Dr. Daniel Kraft
Physician-Scientist, Innovator, & Entrepreneur, Founder & Partner - NextMed Health and Continuum Health Ventures
Daniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, entrepreneur, and innovator and is serving as the Chair of the XPRIZE Pandemic & Health Alliance. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as faculty chair for Medicine at Singularity University since its inception in 2008, and in 2011 founded Exponential Medicine, a program (now evolved to NextMed Health) that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children's Hospital, and fellowships in hematology, oncology, and bone marrow transplantation at Stanford.
Daniel's academic research has focused on: stem cell biology and regenerative medicine, stem cell-derived immunotherapies for cancer, bioengineering human T-cell differentiation, and humanized animal models. His research has been published in journals that include Nature and Science. His clinical work has focused on: bone marrow / hematopoietic stem cell transplantation for malignant and non-malignant diseases in adults and children, medical devices to enable stem cell based regenerative medicine, including marrow derived stem cell harvesting, processing and delivery.
He is heavily involved in digital health, founded Digital.Health, and is on the board of Healthy.io and advises several Fortune-50 and digital health-related startups. Daniel recently founded IntelliMedicine, focused on personalized, data-driven, precision medicine. He is also the inventor of the MarrowMiner, an FDA-approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell-based regenerative therapies.